Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2019 Jan 09

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Giornale Italiano di Dermatologia e Venereologia 2019 Jan 09

DOI: 10.23736/S0392-0488.18.06032-7

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Use of fumaric acid derivatives (FADs) in Italian reference centres for psoriasis

Giovanni DAMIANI 1, 2, 3 , Simone CAZZANIGA 3, 4, Luigi NALDI 3, 5, PsoReal Study Group 

1 Young Dermatologists Italian Network (YDIN), Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy; 2 Clinical Dermatology, Department of Biomedical, Surgical and Dental Sciences, IRCCS Galeazzi Orthopaedic Institute, University of Milan, Milan, Italy; 3 Centro Studi GISED, Bergamo, Italy; 4 Department of Dermatology, Inselspital University Hospital, Bern, Switzerland; 5 Department of Dermatology, Ospedale san Bortolo, AULSS8, Vicenza, Italy


PDF


BACKGROUND: Several therapies are available for psoriasis, including in some countries oral fumaric acid derivatives (FADs). Even if FADs are not available in the Italian market, they can be prescribed and reimbursed by the National Health Service, on request from the treating physician, when considered as a valuable option in selected patient.
METHODS: We performed a retrospective analysis of the PsoReal registry data, restricted to adult psoriatic patients enrolled between 2009 and 2017. Demographic and clinical data were collected together with information on systemic therapies prescribed for psoriasis, drug shifts and adverse effects. We focused our analysis on FADs compared with other systemic drugs.
RESULTS: From the registry data, a total of 17,064 patients were extracted, and 11,592 patients (67.9%), fulfilled inclusion criteria. The majority of them had chronic plaque psoriasis, the mean disease duration was 17.1 ± 12.6 years, and the mean PASI was 17.8 ± 10.9, with 51.5% presenting a moderate Ps (PASI between 10 and 20). A total of 36 patients (0.3%) were treated by FADs. The average treatment duration of conventional (9.0 ± 10.0 months) and biological agents (13.7 ± 11.6 months) was lower compared to the duration of FADs (28.1 ± 20.1, p-value<0.001). FADs were used at an average dosage of 361.0 ± 146.3 mg/day and FADs treated patients displayed an overall lower healthcare cost compared with other drugs.
CONCLUSIONS: The current study confirms previous European data about efficacy and safety of FADs, and suggests a decrease of healthcare costs for FADs treated patients as compared to other treatments.


KEY WORDS: Psoriasis - Fumaric acid - Safety - Adverse effects - Hospitalization

inizio pagina